Preparation of semaglutide long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics
As tirzepatide facilitates weight reduction, obesity-associated cortisol abnormalities may improve secondarily in some individuals
Ethics declarations Ethics Approval No human studies were carried out by the authors for this article
With the 1.75 mg SC dose, the effect on blood pressure is smaller but still present
including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use